FE Baraka Dori Farm, Llc

FE Baraka Dori Farm, Llc is a pharmaceutical importer based in Tashkent, Uzbekistan. The company specializes in the procurement of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, primarily sourced from India. With a total import value of $2.6 million USD across 99 shipments, FE Baraka Dori Farm demonstrates a focused approach to sourcing specific pharmaceutical products. The company's portfolio is concentrated on two therapeutic categories: antifungals and vitamins & supplements, with antifungals comprising 98% of their imports. This strategic focus indicates a targeted effort to meet the demand for these therapeutic areas within the Uzbekistani market.

While specific details about FE Baraka Dori Farm's warehouse locations and logistics capabilities are not publicly disclosed, the company's consistent import activity suggests a well-established distribution network within Uzbekistan. The primary port of entry for these pharmaceutical products is Tashkent, the capital city, which serves as a central hub for distribution throughout the country. Given the volume and frequency of imports, it is likely that the company operates multiple warehouses to facilitate efficient storage and distribution, ensuring timely delivery to various regions within Uzbekistan.

FE Baraka Dori Farm, Llc functions as a primary wholesaler in Uzbekistan's pharmaceutical supply chain. By importing finished pharmaceutical formulations and distributing them domestically, the company plays a crucial role in ensuring the availability of essential medications across the country. Their focus on specific therapeutic categories, particularly antifungals, positions them as a key player in meeting the healthcare needs related to these treatments.

The company's sourcing strategy exhibits a high degree of concentration, with 100% of their pharmaceutical imports originating from a single supplier, KUSUM HEALTHCARE PRIVATE LIMITED in India. This single-source dependency could pose risks, such as supply chain disruptions due to geopolitical issues, regulatory changes, or operational challenges faced by the supplier. However, the consistent volume of imports and the long-standing relationship indicated by the data suggest a stable and reliable partnership. The strategic choice to concentrate sourcing from one supplier may also allow for better negotiation terms and streamlined logistics.

FE Baraka Dori Farm's supply chain resilience appears to be closely tied to the stability of KUSUM HEALTHCARE PRIVATE LIMITED. The absence of backup suppliers and the lack of diversification in sourcing could make the company vulnerable to disruptions. Additionally, the limited diversity in imported formulations, with only 234 unique products, may restrict the company's ability to adapt to changing market demands or regulatory requirements. Ensuring that KUSUM HEALTHCARE maintains high standards of quality and compliance with international regulations is essential for mitigating potential risks.

The concentrated sourcing pattern positions FE Baraka Dori Farm as a specialized distributor of specific pharmaceutical products within Uzbekistan. For Indian exporters, this presents an opportunity to establish a strong partnership by meeting the company's specific product requirements and quality standards. However, potential suppliers should be prepared to meet the demands of a single-source relationship, which may include higher volumes and stringent compliance with regulatory standards.

In Uzbekistan, the State Sanitary and Epidemiological Surveillance Service (SSESS) is the primary regulatory authority overseeing pharmaceutical imports. Key legislation governing pharma imports includes the Law on Medicines and Pharmaceutical Activities, which outlines the requirements for the import, registration, and distribution of pharmaceutical products. The marketing authorization pathway for Indian generics involves obtaining a certificate of conformity from the SSESS, ensuring that imported products meet the country's safety, efficacy, and quality standards.

Import licensing requirements in Uzbekistan stipulate that pharmaceutical importers must obtain an import license from the SSESS, which involves submitting detailed documentation about the products, including their composition, manufacturing process, and intended use. Recognition of Good Manufacturing Practice (GMP) certificates is crucial; certificates from recognized authorities such as the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S) are typically accepted. Additionally, importers must hold a wholesale distribution authorization to legally distribute pharmaceutical products within the country.

Imported pharmaceutical products are subject to batch testing to ensure they meet the required quality standards. Stability requirements are enforced to guarantee that products remain effective throughout their shelf life. Labeling must be in the Uzbek language, providing clear information on dosage, administration, and storage conditions. Serialization mandates are in place to track and trace products throughout the supply chain, enhancing transparency and reducing the risk of counterfeit products entering the market.

Between 2024 and 2026, Uzbekistan implemented several policy changes affecting pharmaceutical imports. These include stricter enforcement of GMP standards, updated labeling requirements to include additional safety information, and enhanced regulatory scrutiny of import licenses to ensure compliance with international standards. These changes aim to improve the quality and safety of pharmaceutical products available in the Uzbekistani market.

FE Baraka Dori Farm's focus on importing antifungal medications, particularly ketoconazole, aligns with the therapeutic needs of the Uzbekistani population. The high import value of ketoconazole suggests a significant demand for antifungal treatments, possibly due to prevalent fungal infections or a lack of domestic production in this category. The inclusion of biotin in their portfolio indicates an interest in vitamins and supplements, catering to the growing health and wellness market in Uzbekistan.

The company's sourcing strategy is centered on generic drugs, primarily from India, which offers cost-effective manufacturing and a wide range of pharmaceutical products. The preference for finished pharmaceutical formulations allows for quicker market entry and reduces the complexities associated with raw material sourcing and manufacturing. India's established reputation in pharmaceutical manufacturing and its compliance with international quality standards make it a suitable partner for FE Baraka Dori Farm.

Based on its product mix, FE Baraka Dori Farm serves the wholesale distribution segment of the Uzbekistani pharmaceutical market. By importing and distributing specific therapeutic products, the company ensures that essential medications are available to pharmacies, hospitals, and clinics across the country, thereby supporting the overall healthcare infrastructure.

There is a realistic opportunity for new Indian suppliers to enter the Uzbekistani market by meeting the specific product requirements of FE Baraka Dori Farm. Gaps in the company's current sourcing include a limited range of imported formulations and a lack of diversification in suppliers. Potential suppliers can capitalize on these gaps by offering a broader range of products, ensuring compliance with Uzbekistani regulatory standards, and establishing reliable supply chains to meet the company's needs.

Indian exporters aiming to supply FE Baraka Dori Farm must obtain GMP certificates recognized by the SSESS, such as EU GMP, WHO GMP, or PIC/S. They must also ensure that their products comply with Uzbekistani labeling requirements, including the use of the Uzbek language and adherence to serialization mandates. Establishing a reliable supply chain capable of meeting the importer's volume and quality demands is essential.

To build a relationship with FE Baraka Dori Farm, Indian exporters should initiate contact through formal channels, providing detailed product information, certifications, and compliance with Uzbekistani regulations. Participating in relevant tenders and trade fairs can enhance visibility and credibility. Developing a comprehensive regulatory filing strategy, including obtaining the necessary import licenses and GMP certifications, is crucial. Setting realistic timelines for product registration and market entry, considering the regulatory processes in Uzbekistan, will facilitate a smoother collaboration.